Status:

COMPLETED

The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers

Lead Sponsor:

Hanmi Pharmaceutical Company Limited

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

19-45 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2001 and HGP2001 in healthy volunteers.

Eligibility Criteria

Inclusion

  • 19 kg/m\^2 ≤ BMI \< 28 kg/m\^2, weight \>60kg
  • 90 mmHg ≤ SBP \<140 mmHg, 50 mmHg ≤ DBP \<900 mmHg
  • agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug.

Exclusion

  • A history of hypersensitivity reactions or clinically significant hypersensitivity reactions
  • A history of gastrointestinal diseases or surgery that may affect the absorption of clinical trial drugs
  • A history of substance abuse or who test positive for drugs of concern for abuse in the urine drug screening test
  • Positive results of serological tests
  • Have taken other investigational drugs or bioequivalence drugs within 6 months before the first administration of the investigational drug
  • Donated whole blood within 60 days prior to the screening date or donated components within 30 days or received a blood transfusion within 30 days
  • Have drank more than 210 g/week of alcohol within 30 days before the screening date
  • Have smoked more than 10 bills/day within 30 days before the screening date
  • AST, ALT value is more than 2 times the UNL or bilirubin level is more than 1.5 times the UNL, eGFR \< 50 mL/min/1.73m2, Prothrombin (INR) \> 1.31 INR or aPTT \> 39.7 sec
  • 12-ECG QTc \>450 ms

Key Trial Info

Start Date :

January 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 8 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04764201

Start Date

January 16 2021

End Date

March 8 2021

Last Update

April 1 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jeonbuk University Hospital

Jeonju, South Korea